Histopathological study of the effects of a single intratracheal instillation of surface activeagents on lung in rats.

Abstract

Pulmonary drug administration of most peptide/protein drugs is characterized by low bioavailability due to low permeability. Surface active agents have been tested as an absorption enhancer, but few studies have been carried out on the local toxicity of these additives. In the present study, to clarify the toxic effects of surface active agents on the lung, a relatively high concentration (1%) of polyoxyethylene 9 lauryl ether (Laureth-9) and sodium glycocholate (SGC) was given to rats in a single intratracheal instillation (100 microliters/rat), and the lung was evaluated histopathologically. In the rats treated with Laureth-9, lung lesions were observed in the bronchi to alveoli. At 1 day after administration, edema, hemorrhage and inflammatory cell infiltration due to degeneration and desquamation of epithelium were observed. At 3 and 7 days after administration, the wound healing process resulting from the lung injury, such as hyperplasia of epithelium and sporadic fibrosis, was noted. SGC also induced lung lesions with a similar histopathological nature, whereas the lesions were mostly confined to the alveoli. These results suggest that surface active agents induce acute inflammation of the lung by intratracheal instillation, that the distribution of lesions is different among surface active agents, and moreover that pathological examination is indispensable for clarifying local toxicity of absorption enhancers in pulmonary drug-delivery studies.

Enhanced physical stabilization of fenofibrate nanosuspensions via wet co-milling with a superdisintegrant and an adsorbing polymer

“…Moreover, ionic surfactants in oral drug formulations present challenges such as incompatibilities with other ionic molecules, sensitivity to pH, salt or temperature changes, GIT irritation, and toxicity. A more serious issue with surfactants is that they can be toxic if used in excess [5] especially in inhalation products [22,23]. Therefore, surfactants should be used sparingly to minimize all potential negative impact or should be eliminated completely, if possible, for certain pharmaceutical applications.…”

Pure Insulin Nanoparticle Agglomerates for Pulmonary Delivery

“…One potential drawback to these formulations is that they contain excipients, which aid in manufacturing and aerosol performance, but may have unforeseen negative impacts on the long-term respiratory health of the patient 2, 17. Of particular concern are penetration enhancers, such as polyoxyethylene 9 lauryl ether and sodium glycocholate, which have been shown to induce acute inflammation in the lung 20. It may therefore be desirable to create an inhalable form of insulin that does not contain excipients so as to avoid any potential complications that might arise.…”

Effect of Pulmonary Surfactant and Phospholipid Hexadecanol Tyloxapol on Recombinant Human-Insulin Absorption from Intratracheally Administered Dry Powders in Diabetic Rats

“…Suzuki et al 21) demonstrated that high dose surfactants could induce acute lung inflammation under higher concentrations. Although it is not examined whether this effect exists under normal concentrations, this study revealed the potential toxicological effect of surfactants.…”